ClinicalTrials.gg
CompletedNCT04675528FEELUpdated Jul 25, 2024

Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) FEEL Study

A Phase 1 interventional study of DHP107(Oral paclitaxel) in Advanced Solid Tumor, sponsored by Daehwa Pharmaceutical Co., Ltd.. Completed at 5 sites in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-25.

Sponsored by Daehwa Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the food effect on pharmacokinetics of DHP107 in patients with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Advanced Solid Tumor
  • Liporaxel
  • DHP107
  • Oral paclitaxel
03

In context

Lead sponsor

Daehwa Pharmaceutical Co., Ltd. is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are ≥18 years of age on the date of written .
  2. Subjects with or cytologically confirmed advanced solid tumors including but not limited to the listed below for which paclitaxel monotherapy has been determined an appropriate therapy at the investigator's discretion.

    • Angiosarcoma
    • Bladder cancer
    • Breast cancer
    • Cervical cancer
    • Head and neck cancer (if no difficulty with swallowing)
    • Kaposi's sarcoma
    • Lung cancer
    • Ovarian cancer
  3. Subjects who have a of ≥12 weeks.
  4. Subjects who are able to take oral medication.
  5. Subjects who have a performance status of ≤ 2 on the (ECOG) scale.
  6. Subjects who have evaluable disease according to the Version 1.1 (RECIST version 1.1).
  7. Subjects who have adequate organ functions as indicated by the following laboratory values:
  8. Subjects who are willing and able to comply with scheduled visits, treatment plans, laboratory tests, and procedures.
  9. Subjects who have voluntarily agreed to participate by giving written informed consent.
  10. Women of who have negative pregnancy test results at the screening visit and men with female partners of childbearing potential must agree to use adequate for the duration of the trial and up to 90 days after last dose of study drug

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have history of severe hypersensitive reaction to the active ingredient or any of DHP107.
  2. Subjects with following surgical history/medical conditions that may affect drug absorption:
  3. Subjects who developed cardiovascular disease (unstable angina, myocardial infarction, stroke, and ) within 24 weeks prior to study entry, which is deemed to be by the investigator.
  4. Subjects with known active or C infection, or hepatobiliary disease, or known history of immunodeficiency virus infection (However, subjects with Gilbert's Syndrome, asymptomatic gallstones, or stable chronic liver disease are, at the discretion of the investigator, eligible for the study. Subjects who are hepatitis B carriers may be eligible if they are on antiviral therapy 2 weeks prior to study entry).
  5. Subjects with neuropathy grade > 2 based on v5.0 at the time of study entry.
  6. Subjects with uncontrolled medical or mental illness that, in the investigator's judgement, could affect treatment tolerability or compliance.
  7. Subjects diagnosed with other malignant primary tumor with an exception of the following:

    • diagnosed at least 5 years previously without evidence of recurrence or persistent disease
    • The complete excision of basal/squamous cell carcinoma or papillary thyroid carcinoma or the complete treatment of cervical intraepithelial neoplasia or other in situ carcinoma
  8. Subjects with symptomatic or unstable, untreated to the central nervous system (CNS) at the time of screening ('Unstable' means worsening of symptoms within 4 weeks prior to screening).
  9. Subjects who are currently receiving alternative cytotoxic agents, regular systemic and medications that could influence drug absorption (e.g. H2-antihistamines, antacids, metoclopramide and charcoal) within 4 weeks prior to entry into the study (C1D1).
  10. Subjects who are currently receiving (or unable to stop use the 3 days before the first dose of DHP107 and throughout the study) prescription or non-prescription medications or other products known to be moderate or potent inhibitors/inducers of , P-gp, or CYP2C8.
  11. Subjects who cannot intake whole high fat meal offered.
  12. Pregnant or breastfeeding women.
  13. Subjects who have received any drugs or devices within 4 weeks before the first day of study treatment (C1D1)
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Fasting treatment

    Drug: DHP107(Oral paclitaxel)

  • Experimental
    Fed treatment

    Drug: DHP107(Oral paclitaxel)

Interventions

  • DHP107 200 mg/m\^2 orally twice daily on Day 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m\^2 orally once daily on Day 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)

    Also known as: Liporaxel®

06

What researchers measure

Primary outcomes

  1. • Cmax

    The primary endpoints of this trial are the ratio of geometric means of the following pharmacokinetic parameters following DHP107 administration fed with fasting condition

    Time frame: Day 1 and Day 8 of Cycle 1(each cycle is 28 days)

  2. • Tmax

    and the median difference of the following pharmacokinetic parameters following DHP107 administration fed with fasting condition:

    Time frame: Day 1 and Day 8 of Cycle 1(each cycle is 28 days)

07

Study locations

5 sites
  • University of Semmelweis, 1st Internal Medicine Clinic, Department of Clinical Pharmacology
    Budapest, 1083, Hungary
  • National Institute of Oncology
    Budapest, 1122, Hungary
  • University of Debrecen-Clinical Center, Internal Medicine Clinic, Department of Clinical Pharmacology
    Debrecen, 4032, Hungary
  • Clinexpert Ltd Phase I. Studycenter
    Gyöngyös, 3200, Hungary
  • University of Szeged, Dermatology and Allergology Clinic, Phase I. Investigational site
    Szeged, 6720, Hungary
08

References and documents

Publications

  • Hitre E, Lang I, Pall D. A randomized, open-label, two-way crossover clinical trial to evaluate the food effect on pharmacokinetics and safety of DHP107 in patients with advanced solid tumors: the FEEL study. Cancer Chemother Pharmacol. 2026 May 30;96(1):59. doi: 10.1007/s00280-026-04887-9. PubMed 42215716 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Dec 2022, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2020
First posted
Dec 19, 2020
StartActual
May 4, 2021
Primary completionActual
Dec 12, 2022
CompletionActual
Dec 12, 2022
Last update
Jul 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04675528
Lead sponsor
Daehwa Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Dec 19, 2020
Start date
May 4, 2021
Primary completion
Dec 12, 2022
Completion
Dec 12, 2022
Last update
Jul 25, 2024

Study contacts

Erika Hitre, M.D., Ph.D
principal investigator · National Institute of Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion